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Cu is an essential nutrient for man, but can be toxic if intakes are too high. In sensitive populations, marginal over- or under-exposure can have
detrimental effects. Malnourished children, the elderly, and pregnant or lactating females may be susceptible for Cu deficiency. Cu status and
exposure in the population can currently not be easily measured, as neither plasma Cu nor plasma cuproenzymes reflect Cu status precisely.
Some blood markers (such as ceruloplasmin) indicate severe Cu depletion, but do not inversely respond to Cu excess, and are not suitable to indi-
cate marginal states. A biomarker of Cu is needed that is sensitive to small changes in Cu status, and that responds to Cu excess as well as
deficiency. Such a marker will aid in monitoring Cu status in large populations, and will help to avoid chronic health effects (for example,
liver damage in chronic toxicity, osteoporosis, loss of collagen stability, or increased susceptibility to infections in deficiency). The advent of
high-throughput technologies has enabled us to screen for potential biomarkers in the whole proteome of a cell, not excluding markers that
have no direct link to Cu. Further, this screening allows us to search for a whole group of proteins that, in combination, reflect Cu status. The
present review emphasises the need to find sensitive biomarkers for Cu, examines potential markers of Cu status already available, and discusses
methods to identify a novel suite of biomarkers.
Copper status: Copper excess: Copper deficiency: Public health: Biomarkers
Copper essentiality and toxicity
Cu is an essential micronutrient for man, but potentially toxic
when intake levels are too high. As a transition metal, it takes
part in a variety of biological reduction and oxidation (redox)
processes. This makes it important as a cofactor of many
redox enzymes, but Cu overload can also lead to participation
in the Fenton-type redox reaction and cause oxidative damage
to cells1.
Cu deficiency, especially during pregnancy, has widespread
effects. It can result in impaired heart and blood vessel devel-
opment and in brain malformation in the fetus2–4. Low Cu
levels have been linked with bone malformation during devel-
opment5,6, and may contribute to the risk of developing osteo-
porosis later in life7,8. A decrease in collagen stability9 and
impaired melanin synthesis can also be consequences of low
Cu status10,11. Cu deficiency has also been associated with a
weakened immune system and an increase in infections (for
a review, see Bonham et al.12), with a decline in cardiovascu-
lar health (for a review, see Uriu-Adams & Keen1) and
adverse alterations in cholesterol metabolism13–15. Further,
oxidative stress is a consequence of Cu deficiency1, and –
although controversial – low plasma Cu has been linked
with a faster decline in cognitive ability in Alzheimer’s dis-
ease16,17. Finally, Cu deficiency affects the metabolism of
other trace elements; most notably it perturbs Fe mobilisation
and can cause secondary Fe deficiency18. Because of the com-
plexity and variety of the symptoms, it is often difficult to
diagnose Cu deficiency, rather than other nutritional
deficiencies.
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Cu deficiency is extremely prevalent in malnourished
children19,20. A recent study in twenty-nine severely or
moderately malnourished children demonstrated that all
patients were Cu deficient at time of hospitalisation
(M Medina and M Araya, unpublished results). Sub-popu-
lations at an elevated risk of Cu deficiency include pregnant
and lactating women, as well as children during prenatal and
neonatal life and during breast-feeding. Disease conditions
such as gut absorption problems (coeliac disease, Crohn’s dis-
ease), or diseases of the immune system (for example, AIDS,
all autoimmune diseases) may pose a risk for Cu deficiency.
Since many foods high in Cu (liver, oysters, chocolate) are
high in fat and not considered part of a healthy lifestyle, Cu
deficiency may be a side effect of dieting, especially in
young women. Prolonged use of Zn supplements may cause
secondary Cu deficiency, as Zn causes an induction of metal-
lothioneins, which then also bind Cu21. Further, Zn and Cu
compete for intestinal uptake22–24. Excessive Zn intake has
been shown to cause secondary Cu deficiency in several
case studies25–27, and the consequences of supplementing
large segments of the population with moderate or high
doses of a single mineral are unknown.
Cu overload is much less likely than Cu deficiency, at least
in part since there are very efficient homeostatic mechanisms.
Possible targets of Cu overload are mainly the liver and the
brain. Cu overload, like Cu deficiency, can lead to cellular
oxidative stress. Patients with any liver disease (all forms of
hepatitis, alcohol abuse) are sensitive to Cu-related liver tox-
icity and diabetes has also been linked with high liver
Cu1,28. There are also subpopulations with a genetic predispo-
sition that may have an elevated risk of Cu accumulation.
These include patients suffering from Wilson’s disease (WD),
caused by mutations in the Cu ATPase ATP7B29. ATP7B is a
Cu pump responsible for Cu excretion, and WD patients
accumulate Cu to toxic levels. WD is an autosomal recessive
disorder, and occurs at a frequency of 1 in 30 000.
The prevalence of WD heterozygotes, individuals who carry
one WD and one healthy allele of ATP7B, is not known. Het-
erozygotes appear perfectly healthy, but they may have mild
abnormalities in Cu metabolism30. These individuals represent
a potential public health problem, as they are generally una-
ware of their condition. At least in principle, they could be
more sensitive to high Cu intake, but without good markers
of Cu status, no evidence is available.
Copper exposure and copper status in large populations
In man, Cu is supplied in the diet and to varying degrees by
drinking water from Cu piping. Good dietary sources of Cu
are organ meat (liver), some seafoods (oysters), chocolate
and cocoa products, nuts (mainly cashew) and seeds.
According to the US National Academy of Sciences (http://
math.ucsd.edu/,ebender/Health%20&%20Nutrition/Nutrition
/NAS.html), the RDA, or the adequate intake of Cu is 0·9mg
for the general population. The upper limit is 10mg. Pregnant
and nursing women need more Cu, with an RDA of 1mg and
an adequate intake of 1·3mg. The National Academy of
Sciences states that Cu deficiency is common, and experts
conclude from the ‘EU Voluntary Risk Assessment for
copper and copper compounds’ that Cu deficiency may be
more common than generally thought in Europe.
Despite the realistic possibility of widespread mild Cu
deficiency, many regulatory agencies, such as the Californian
Environmental Protection Agency, are concerned about poten-
tial Cu overexposure (for example, through drinking water).
However, Cu status in the population is not easily measured,
as neither plasma Cu nor plasma cuproenzymes reflects Cu
status31–33. Cu status is often estimated by intake and
exposure assessments. These are subject to the error inherent
to all dietary intake studies and, while suitable for the assess-
ment of macronutrient intake, may not be precise enough to
estimate intake of a dietary micronutrient.
The limit for Cu in drinking water according to the WHO is
2mg/l. This limit is not wholly adopted; for example, the US
limit is 1·3mg/l and many European countries have a limit of
1mg Cu/l. The reason for this inconsistency is a question of
regulatory principles. Local changes in the chemical properties
of drinking water (water hardness and pH) can also lead to
variations in Cu content of the water.
Regulators are currently not sure what limit makes drinking
water ‘safe to drink’ in all situations. Taken together with the
potentially large error of dietary Cu intake assessment, regula-
tors and public health professionals adopt a predominantly
conservative approach in Cu-exposure regulation. This
approach may not be suitable for an essential trace metal,
since a low intake of Cu is as dangerous as a too-high intake.
A good biomarker of Cu is needed, therefore, to monitor and
avoid chronic health effects in large populations, and to give an
‘early warning’ in sensitive populations (infants, pregnant or
lactating women, individuals with idiopathic or genetic changes
in metabolism, the elderly, disease), before any tissue damage
occurs. While it is possible to detect Cu deficiency or excess
in their extremes due to ensuing tissue damage (for example,
an increase in liver enzymes), it is currently not possible to
detect minor but biologically significant variations of Cu
status33,34. This situation poses an urgent need to develop a
‘diagnostic test kit’ of Cu status to satisfy regulators and to
ensure adequate public health decisions. The biomarker(s)
must be able to measure Cu status, including mild deficiency
and mild overload, sensitively and specifically.
Copper homeostasis: liver copper and regulation of plasma
copper levels
Newly absorbed Cu is transported from the intestine via the
portal vein directly to the liver. Here, Cu is stored and redis-
tributed to all other organs35,36. Cu status in the body is regu-
lated by both duodenal absorption and/or biliary excretion. As
long as exposure is within the homeostatic range, in healthy
adults high Cu exposure results in down regulation of Cu
uptake in the duodenum, and up regulation of biliary
excretion36–39. As a result, high Cu exposure or intake does
not necessarily cause an equivalent body ‘Cu load’. This is
one of the reasons why Cu status cannot be estimated by
exposure levels. Currently, the only precise indicator of Cu
load is the Cu content in the liver33,40, not something that
can be readily measured in human subjects.
Plasma Cu is very tightly regulated and does not correspond
to Cu status (liver Cu). Its measurement is made more com-
plex by the fact that most Cu in serum is in the protein ceru-
loplasmin (Cp), and its regulation may reflect regulation of the
protein, rather than of Cu levels.
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Proteins binding copper and their role as biomarkers
Many enzymes require Cu for their function, covering a wide
range of biological processes. Some of the Cu-requiring
enzymes, binding proteins (both intra- or extracellular) and
the intracellular Cu chaperones are listed in Table 1. A large
number of enzymes need Cu, and many proteins bind and
transport Cu. However, no single protein reflects Cu status
precisely via its expression level.
Traditional markers of copper status
The traditional approach to the measurement of Cu status has
been to use cuproenzymes or total Cu levels in plasma as mar-
kers. However, about 95% of plasma Cu is bound to Cp41,
with the remainder bound by albumin or di-histidine com-
plexes. Cp is an azide-sensitive ferroxidase, and this character-
istic enzyme activity is clinically used to estimate plasma Cp
levels. It binds between six and eight Cu ions per mol-
ecule42,43. Cp is generally lower in men than in women44,45,
and is increased by oestrogen, pregnancy and the contracep-
tive pill. Cp also is an acute-phase reactant, explaining its
increase during inflammation, infections and rheumatoid
arthritis46. Being an acute-phase response protein, Cp
increases also in patients with myocardial complications and
in cancer patients47–49. Further, it is age dependent50 and sub-
ject to seasonal changes51. Due to these limitations, Cp cannot
be considered a marker for Cu excess52. Since serum Cu is a
reflection of Cp, the same limitations apply to serum Cu.
There is a wealth of data showing that Cp levels decrease in
severe Cu deficiency53. Cp may, therefore, be a good indicator
of Cu deficiency in man, especially when measured from the
individual baseline level.
Since Cp levels in plasma remain fairly stable when Cu
intake increases, it has been proposed that changes in Cu
load may be reflected by the non-Cp Cu fraction. However,
the available evidence does not support this idea. The non-
Cp fraction cannot be measured directly, and is usually esti-
mated by calculating the amount of Cu contained in Cp
(assuming that each Cp molecule contains a mean of six
atoms of Cu). This estimated amount is then subtracted from
total Cu in the serum. There are several flaws with this
approach. The result obtained is a direct function of Cp con-
tent in the plasma, with all the implied errors. For example,
when non-Cp Cu values are used in clinical practice, a signifi-
cant number of patients have ‘negative values’. This may be
caused by errors in Cp measurement or by the variability in
Cu atoms bound per Cp molecule, and strongly suggests that
non-Cp-bound plasma Cu is not a suitable biomarker for Cu.
Erythrocyte Cu,Zn superoxide dismutase (SOD)-1 has been
tested as a biomarker of Cu intake in several studies, but has
proven not to be either a reliable or sensitive indicator53. Eryth-
rocyte SOD1 activity in a human trial (men) appeared to be influ-
enced by carbohydrate components of the diet, as it was only a
good biomarker in a high-fructose diet, but not sensitive to Cu
intake if the Cu was fed in a maize-starch diet54. Other human
studies tested the value of erythrocyte SOD1 activity in men
and women, again with negative or equivocal results, for
Table 1. Overview of copper-binding proteins
Protein Function
Cu-requiring enzymes
Extracellular
Cp Plasma multi-copper oxidase necessary for Fe mobilisation; Cu binding and transport in plasma
Extracellular Cu,Zn SOD3 Involved in defence against reactive oxygen species
PAM Peptide post-translational activation, modification of many important neuropeptides
Amine oxidases A group of enzymes oxidising primary monoamines, diamines, and histamine
Lysyl oxidase Deaminates lysine and hydroxylysine residues in collagen or elastin; involved in formation of cross-links
Intracellular
CCO Mitochondrial protein and component of the electron transfer chain
Tyrosinase Catalyst of melanin and other pigment production
Dopamine b mono-oxygenase Involved in catecholamine metabolism, catalyses oxidation of 3,4-dihydroxyphenylethylamine to yield noradrenaline
Intracellular Cu,Zn SOD1 Involved in defence against reactive oxygen species)
Phenylalanine hydroxylase Catalyst of the oxidation of phenylalanine to tyrosine
Hephaestin Intracellular multi-copper ferroxidase
Cu-binding or -transporting proteins
Extracellular
Albumin Cu binding in plasma
Transcuprein Cu binding and transport in plasma
Blood clotting factors V and VIII Blood clotting
Intracellular
Metallothionein Cu storage and superoxide scavenging
Glutathione Metal detoxification
Cartilage matrix glycoprotein Contributes to the structural integrity of the connective tissue
ATP7A Cu transporter
ATP7B Cu transporter
Ctr1 Plasma membrane Cu transporter
Intracellular Cu chaperones
ATOX1 Delivery of Cu to the Cu ATPase ATP7A (Menkes protein) and ATP7B (Wilson protein)
CCS Delivery of Cu to SOD1
Cox17 Delivery of Cu to the mitochondria (chaperone for CCO)
Cp, ceruloplasmin; SOD, superoxide dismutase; PAM, peptidylglycine a-amidating mono-oxygenase; CCO, cytochrome C oxidase; Ctr, Cu transporter; CCS, Cu chaperone for
superoxide dismutase.
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example, a reduction of SOD1 activity in Cu depletion, but no
increase in Cu repletion55, or insensitivity to Cu supplemen-
tation38,52. Like Cp, SOD1 may indicate Cu deficiency, but is
not responsive to excess Cu. A further disadvantage in the
assessment of erythrocyte SOD1 is the lack of a standard
assay, making clinical measurement and comparison between
laboratories difficult. The fact that SOD1 is also an acute-
phase reactant and responds to a variety of health and stress con-
ditions probably also contributes to the variable results.
Platelet cytochrome C oxidase (CCO) has been investigated
as a biomarker for Cu status in a few studies. Male weanling
rats were fed diets containing increasing concentrations of Cu,
covering from a range of Cu deficiencies to a Cu-adequate
diet. A significant reduction of platelet CCO activity was
observed in animals receiving the 3mgCu/g diet, correlating
with a decrease of Cu levels in the liver56. In a study in post-
menopausal women fed a diet containing 0·57mgCu/d for
105 d, followed by a Cu-repletion period of 2mgCu/d for
35 d, CCO was the most sensitive marker, as compared with
plasma Cu, Cp or erythrocyte SOD1. Platelet CCO activity
dropped to 49% during Cu depletion, then increased back to
60% of the control level (entry level) during Cu repletion55.
It is currently unclear whether an increase in Cu status is par-
alleled by an increase in platelet CCO activity. CCO is a labile
enzyme, displaying large inter-subject variation, factors that
may limit its use in the field31.
Plasma diamine oxidase (DAO) activity was reported to be
decreased in rats fed marginal- and low-Cu diets57. This
decline was parallel to a drop in liver Cu, while other cuproen-
zymes remained unaltered. Reduced plasma DAO activity was
also found in Cu-deficient human subjects and in long-term
Cu-deficient rats58. These findings suggest plasma DAO may
be a very sensitive marker for marginal to marked Cu
deficiency. An increase in plasma DAO activity, however, is
indicative of tissue injury and used clinically for the detection
of injury of intestinal tissue59,60, excluding it from use as a
wide-range indicator of Cu status. Nonetheless, it may have
value as part of a suite of markers.
Liver aminotransferases are traditionally used as biomarkers
for high Cu status, since Cu is deposited in the liver, and
excess Cu results in liver tissue damage. In a recent trial,
Cu supplementation of 10mg/d was given for 60 d to a
study population with naturally high or low serum Cp. It was
shown that the liver aminotransferases glutamic-oxaloacetic
transaminase, glutamic-pyruvic transaminase and g-glutamyl-
transferase had increased in both groups in response to elev-
ated Cu intake after the 2-month loading period was
completed. While the increase was significant, liver amino-
transferases remained below the clinical cut-off level to indi-
cate liver pathology. This increase was transient, and not
associated with any liver dysfunction, indicating that these
markers may be useful in detecting excess Cu intake within
the subgroups carrying Cu-related polymorphisms (resulting
in a high- or low-Cp phenotype). Further studies to character-
ise these subgroups are clearly needed52.
In a similar trial on subjects with normally distributed
serum Cp levels, study participants ingested 2 to 6mgCu/l
in drinking water. Gastrointestinal symptoms increased in
the Cu-supplemented groups in a dose-dependent manner61,
which was interpreted as a consequence of acute Cu exposure.
However, there was no change in liver enzyme levels in the
serum. Further, since none of these liver enzymes respond to
Cu deficiency, they cannot be considered as reasonable candi-
dates for full-range biomarkers for Cu in a normal population.
A plasma cuproenzyme with potential to be used as a bio-
marker for Cu is peptidylglycine a-amidating mono-oxy-
genase (PAM), the advantage being that a small amount of
blood from a finger-prick sample may be sufficient to detect
changes. In individuals suffering from genetic Cu deficiency
(Menkes’ disease and occipital horn syndrome), plasma
PAM is Cu depleted, leading to a decrease in enzyme activity.
In vitro addition of Cu to blood samples from these patients
repletes PAM activity. This test shows an increased Cu stimu-
lation index of PAM in mild to severe Cu deficiency, when
compared with healthy controls62. PAM activity has been
shown to be generally lower in various models of Cu
deficiency in rodents63. PAM was suggested to be less sensi-
tive to endocrine changes than, for example, Cp, and may
be a useful marker for Cu deficiency during development
and childhood63. It has to be kept in mind that PAM has so
far only been tested in Cu deficiency, and its activity is unli-
kely to increase in parallel with elevated Cu.
Lysyl oxidase is a cuproenzme involved in the formation of
cross-links in collagen and elastin. Hence, high concentrations
of lysyl oxidase are found in connective tissues, such as
tendon and skin64. The functional activity of the enzyme in
tissue is decreased in dietary Cu deficiency64–67, probably
as a result of post-translational processing (Cu incorporation)
of the enzyme68. In parallel, increased dietary Cu causes acti-
vation of lysyl oxidase in chicken tendon69. Despite these
promising findings, the tissue expression pattern (connective
tissue) of lysyl oxidase is not suited for convenient accessibil-
ity. Its use as a biomarker in man is limited.
Expression of proteins, such as metallothionein in the
liver70 and Cu transporter-1 in several organs71, has been
shown to be regulated by Cu status. However, their value as
a biomarker is limited since they are located within organs
that are not readily accessible. If these candidates prove to
be regulated also in accessible tissues (blood erythrocytes
and monocytes, buccal cells), and if sufficiently sensitive
and reliable assays can be established, proteins expressed
highly in liver may serve as a biomarker for Cu.
Non-traditional biomarkers of copper status
Some components of the immune system have been suggested
as a potential biomarker of marginal Cu deficiency. IL-2, but
not TNF-a, was shown to increase in response to Cu sup-
plementation in individuals with naturally low plasma Cp
levels72. This suggests that IL-2 may be an identifier of a
sub-population with a low-Cp phenotype, and may serve as
a biomarker for elevated Cu in this subgroup. Many immune
markers (IL-2 production, neutrophil function, phenotypic
profiling of lymphocyte subsets and the blastogenic response
to T cell mitogens) have been shown to be sensitive to mild
Cu deficiency, and, what is more, Cu repletion has in many
cases restored their function to control levels (for a review,
see Bonham et al.12). The observation that in vitro activity
of T lymphocytes and neutrophils is suppressed by low Cu
intake in adult male rats, but not in females, suggests the
need for further investigation of immune markers in the
whole population73.
Current biomarkers for copper status 679
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114507798951
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 16:44:15, subject to the Cambridge Core terms of use, available at
Another potential marker of a mild decrease in Cu intake is
bone metabolism. A dietary intervention study in adult healthy
men showed that urinary pyridinoline and deoxypyridinoline,
both biomarkers of bone resorption, significantly increased
when the volunteers’ diet was switched from medium
(1·6mg Cu/d) to low (0·7mgCu/d) intake. Conversely, the
urinary bone resorption markers decreased when Cu intake
was elevated from low to high (6mgCu/d) levels. The volun-
teers were exposed to the experimental diets for 8 weeks.
Serum Cp was unaffected in this study74. These findings, how-
ever, were not confirmed in a similar study in females, where
Cu supplements of 0, 3 or 6mgCu/d during 4 weeks did not
affect urinary bone markers75. This discrepancy may be
explained by that fact that bone metabolism responds to sev-
eral dietary and other factors, such as vitamin D levels and
sunlight. The variety of factors influencing bone resorption
makes the interpretation of changes in those markers difficult.
While undoubtedly influenced by dietary Cu, bone markers
may be too complex to be useful as a Cu-specific biomarker.
Cu deficiency causes an elevation in blood lipopro-
teins13,76–79. Despite these findings, blood lipoprotein metab-
olism is not a promising biomarker for Cu status, as too many
other factors, such as diet and lifestyle, affect these
parameters.
Copper chaperones
The discovery of the first Cu chaperone in 1995 has revolutio-
nised our understanding of intracellular Cu trafficking80. After
Cu is transported across the plasma membrane, intracellular
Cu is carried via specific chaperone proteins to Cu-dependent
enzymes directly, or to compartments in which Cu-dependent
enzymes are matured. The three Cu chaperones identified to
date, and conserved from yeast cells to man, are listed in
Table 1. Cox17 delivers Cu to the mitochondria, where it is
ultimately incorporated into CCO. The Cu chaperone for
SOD (CCS) delivers Cu to the metal-binding site of Cu,Zn-
SOD in the cytosol and in the mitochondrial inter-membrane
space. Atox1 delivers Cu to the two mammalian P-type Cu-
transporting ATPases, ATP7A and ATP7B. This ensures
‘safe’ Cu trafficking, and is the basis for the observation
that, in a healthy cell and in a physiological environment, vir-
tually no Cu is unbound. In order to ensure safe intracellular
Cu delivery, chaperones need to respond to Cu exposure in
a very sensitive way. Chaperones are not present in plasma;
however, their expression in blood erythrocytes and white
cells offers a possibility for easy-access measurement.
The most promising candidate for accurate and sensitive Cu
status detection is the CCS. In a rat feeding study, CCS was
reported to be responsive to Cu-marginal and Cu-deficient
diets. CCS expression was measured with a specific antibody
(Western blot) and was shown to increase in a dose–response
fashion with a decrease in Cu intake in liver as well as in
blood erythrocytes81. CCS was also shown to respond to
mild secondary Cu deficiency (induced by Zn supplemen-
tation) in rats82. These finding are confirmed by a study in var-
ious models of Cu deficiency in mice and rats, where CCS
protein was demonstrated to be consistently elevated in Cu
deficiency83,84. This was concomitant with a decrease in
SOD1 level, and the authors suggested using erythrocyte
CCS:SOD1 for the determination of Cu deficiency.
Until recently, it was unclear whether CCS is negatively regu-
lated by excess Cu85. In a recent study, CCS expression was
measured by real-time RT-PCR in peripheral mononuclear
cells isolated from healthy men that were supplemented with
8mgCu/d for 6 months. Peripheral mononuclear cell CCS
mRNA transcripts decreased significantly in the Cu-treated
group after 6 months, strongly suggesting that this may be a
useful indicator of Cu exposure (M Suazo and M Araya, unpub-
lished results). A similar protocolwas applied to a subpopulation
of healthy adults, representing the 5% highest and lowest
extremes in the serum Cp concentration distribution curve. Per-
ipheral mononuclear cells were isolated from study participants
before and after exposure to a single daily does of 10mgCu for 2
months. No change in CCS expression was observed in the low-
Cp phenotype, but in the high-Cp individuals, CCS was
decreased significantly in response to the Cu supplementation
(M Suazo and M Araya, unpublished results). These data,
along with other studies of CCS in animals and cell lines with
Cu deficiency, support the idea that CCS is the most promising
potential marker for deficiency as well as excess states of Cu,
and call for its further characterisation.
Outlook
In summary, while some blood markers may indicate moder-
ate and severe Cu deficiency (Cp, erythrocyte SOD1, PAM,
DAO) there is no good marker for Cu excess, even at a
level where symptoms such as acute nausea and abdominal
pain are reported34,61.
Many of the potential markers of Cu status listed in Table 1
have not been tested yet. Rather than testing each of the cuproen-
zymes, Cu-binding proteins or Cu chaperones for potential use
as a Cu biomarker, the advent of high-throughput technologies
has made it possible to screen for potential biomarkers in the
whole proteome of a cell. This ‘non-hypothesis-driven search’
has the advantage of not excluding markers that have no direct
connection to Cu. Further, the screening allows us to search
for a group of proteins that, in combination, are reflective of
Cu status. Since Cu is involved in so many biological processes,
a good biomarker may be a very downstream product, with no
immediate role in Cu metabolism. This non-exclusive and
open approach may allow for the determination of a novel
type of biomarker: the biomarker suite.
The biomarker suite opens the door to another possibility: it
may be appropriate to develop different groups of sensitive bio-
markers for different population subgroups. Hypothetically, this
may lead to a suite of Cp, immunological markers and bone indi-
cators only for adult males73–75. For example, a suite may con-
tain metallothionein for use only in adults, but not neonates86.
PAM, in turn, may be introduced in a suite for Cu status
during development63. Finally, we expect that this approach
may be extended to the examination of other nutritional states
arising as a consequence of inappropriate nutrition.
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